Trials / Sponsors / Intellia Therapeutics
Intellia Therapeutics
Industry · 9 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Active Not Recruiting | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Hereditary Angioedema | Phase 3 | 2025-01-15 |
| Recruiting | A Phase 3 Study of NTLA-2001 in ATTRv-PN Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease | Phase 3 | 2024-11-22 |
| Withdrawn | NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Lung Disease, Pulmonary Disease, AATD | Phase 1 / Phase 2 | 2024-11-20 |
| Enrolling By Invitation | Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 Hereditary Angioedema | — | 2024-04-12 |
| Recruiting | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (AT Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Phase 3 | 2023-12-13 |
| Recruiting | Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis | — | 2023-07-10 |
| Terminated | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-12-17 |
| Active Not Recruiting | NTLA-2002 in Adults With Hereditary Angioedema (HAE) Hereditary Angioedema | Phase 1 / Phase 2 | 2021-12-10 |
| Completed | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With H Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis | Phase 1 | 2020-11-05 |